Dogwood Therapeutics Inc. has not released specific financial results in the provided document. However, a significant update involves a strategic transaction completed in Q4 2024, where Dogwood acquired Pharmagesic Holdings, including its novel pain development candidate, Halneuron®. As part of this transaction, CKLS, a publicly listed company on the Hong Kong exchange, received 211,383 shares of Common Stock and 2,108.3854 shares of Series A Preferred Stock, which is convertible into 10,000 shares of common stock each, pending shareholder approval. Additionally, a $20 million strategic financing loan from an affiliate of CK Life Sciences International was converted into 284.2638 shares of Series A-1 Preferred Stock in Q1 2025. Upon conversion of the Preferred Stock, CKLS and its affiliates will hold approximately 90% of Dogwood's common stock on a fully diluted basis. No specific guidance or outlook for sales, revenue, or profits has been disclosed in the document.